An Open-label, Multicenter, Phase II Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non?Small-Cell Lung Cancer NSCLC Without Actionable Genomic Alterations.

Brief Summary

Type:
Lung Cancers

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT05186974

Study #:
STUDY00149569

Start Date:
Jul 26, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05186974

View Complete Trial Details & Eligibility at ClinicalTrials.gov